Search Results - "Thal, L.J."

Mild hypercholesterolemia is an early risk factor for the development of Alzheimer amyloid pathology by PAPPOLLA, M. A, BRYANT-THOMAS, WOLOZIN, B, SANO, M, CRUZ-SANCHEZ, F. F, THAL, L. J, PETANCESKA, S. S, REFOLO, L. M, HERBERT, D, PACHECO, J, GARCIA, M. Fabra, MANJON, M, GIRONES, X, HENRY, T. L, MATSUBARA, E, ZAMBON, D

“…Epidemiologic and experimental data suggest that cholesterol may play a role in the pathogenesis of AD. Modulation of cholesterolemia in transgenic animal…”
Get full text

A randomized controlled trial of prednisone in Alzheimer's disease by AISEN, P. S, DAVIS, K. L, THAL, L. J, BERG, J. D, SCHAFER, K, CAMPBELL, K, THOMAS, R. G, WEINER, M. F, FARLOW, M. R, SANO, M, GRUNDMAN, M

Get full text

The decline in synapses and cholinergic activity is asynchronous in Alzheimer's disease by TIRABOSCHI, P, HANSEN, L. A, ALFORD, M, MASLIAH, E, THAI, L. J, COREY-BLOOM, J

“…To determine the timing of cholinergic loss and reduction of synapses in AD. Decrements in neocortical synapses and cholinergic function occur in AD and…”
Get full text

Episodic memory changes are associated with the APOE- epsilon 4 allele in nondemented older adults by Bondi, M.W, Salmon, D.P, Monsch, A.U, Galasko, D, Butters, N, Klauber, M.R, Thal, L.J, Saitoh, T

“…OBJECTIVETo compare the memory performances of nondemented older adults with and without the epsilon 4 allele of the apolipoprotein E (APOE- epsilon 4)…”
Get full text

Intraparenchymal nerve growth factor improves behavioral deficits while minimizing the adverse effects of intracerebroventricular delivery by Pizzo, D.P, Thal, L.J

“…Nerve growth factor (NGF) delivered via intracerebroventricular (ICV) infusion restores behavioral and biochemical deficits in animal models of cholinergic…”
Get full text

192 immunoglobulin G-saporin produces graded behavioral and biochemical changes accompanying the loss of cholinergic neurons of the basal forebrain and cerebellar Purkinje cells by Waite, J.J., Chen, A.D., Wardlow, M.L., Wiley, R.G., Lappi, D.A., Thal, L.J.

“…Immunolesions of the cholinergic basal forebrain were produced in rats using various intraventricular doses of the immunotoxin 192 immunoglobulin G-saporin:…”
Get full text

Steroid-induced elevation of glucose in Alzheimer’s disease: relationship to gender, apolipoprotein E genotype and cognition by Aisen, P.S, Berg, J.D, Craft, S, Peskind, E.R, Sano, M, Teri, L, Mulnard, R.A, Thomas, R.G, Thal, L.J

“…Glucose and insulin may play an important role in the pathophysiology and symptomatology of Alzheimer s disease (AD), and prior studies suggest interactions…”
Get full text

Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology by Doody, R S, Stevens, J C, Beck, C, Dubinsky, R M, Kaye, J A, Gwyther, L, Mohs, R C, Thal, L J, Whitehouse, P J, DeKosky, S T, Cummings, J L

“…To define and investigate key issues in the management of dementia and to make literature-based treatment recommendations. The authors searched the literature…”
Get full text

Meta-analysis of double blind randomized controlled clinical trials of acetyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimerʼs disease by Montgomery, Stuart A, Thal, L.J, Amrein, R

“…The efficacy of acetyl-L-carnitine (gamma-trimethyl-β-acetylbutyrobetaine (Alcar) in mild cognitive impairment (MCI) and mild (early) Alzheimerʼs disease (AD)…”
Get full text

Cholinergic dysfunction in diseases with Lewy bodies by TIRABOSCHI, P, HANSEN, L. A, ALFORD, M, SABBAGH, M. N, SCHOOS, B, MASLIAH, E, THAL, L. J, COREY-BLOOM, J

“…To evaluate cholinergic activity in diseases with Lewy bodies (LB; LB variant of AD [LBV], diffuse LB disease [DLBD], and Parkinson's disease [PD]) to…”
Get full text

Incidence of and risk factors for hallucinations and delusions in patients with probable AD by PAULSEN, J. S, SALMON, D. P, THAL, L. J, ROMERO, R, WEISSTEIN-JENKINS, C, GALASKO, D, HOFSTETTER, C. R, THOMAS, R, GRANT, I, JESTE, D. V

“…To examine the incidence of and risk factors for hallucinations and delusions associated with patients clinically diagnosed with probable AD. Estimates of the…”
Get full text

Treatment of agitation in AD : A randomized, placebo-controlled clinical trial by TERI, L, LOGSDON, R. G, TARIOT, P, MELLOW, A. M, AUCHUS, A. P, GRUNDMAN, M, THOMAS, R. G, SCHAFER, K, THAL, L. J, PESKIND, E, RASKIND, M, WEINER, M. F, TRACTENBERG, R. E, FOSTER, N. L, SCHNEIDER, L. S, SANO, M, WHITEHOUSE, P

“…Treatment of agitation is a crucial problem in the care of patients with AD. Although antipsychotic and antidepressant medications and behavior management…”
Get full text

A 1-year controlled trial of acetyl-L-carnitine in early-onset AD by THAL, L. J, CALVANI, M, AMATO, A, CARTA, A

“…To determine the efficacy of acetyl-l-carnitine (ALCAR) on the rate of decline in early-onset AD patients. A 1-year, multicenter, double-blind,…”
Get full text

Abnormal verbal event related potentials in mild cognitive impairment and incipient Alzheimer's disease by Olichney, J M, Morris, S K, Ochoa, C, Salmon, D P, Thal, L J, Kutas, M, Iragui, V J

“…Background: It has been reported that patients with amnesia have a reduced effect of word repetition upon the late positive component of the event related…”
Get full text

Nursing home placement is related to dementia progression : Experience from a clinical trial by KNOPMAN, D. S, BERG, J. D, THOMAS, R, GRUNDMAN, M, THAL, L. J, SANO, M

Get full text

Meta-analysis of double blind randomized controlled clinical trials of acetyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer??s disease by Montgomery, Stuart A., Thal, L.J., Amrein, R.

Get full text

Lu 25-109, a muscarinic agonist, fails to improve cognition in Alzheimer's disease by THAL, L. J, FORREST, M, LOFT, H, MENGEL, H

Get full text

A multicenter, randomized, placebo controlled, multiple-dose, safety and pharmacokinetic study of AIT-082 (Neotrofin™) in mild Alzheimer's disease patients by Grundman, M, Capparelli, E, Kim, H.T, Morris, J.C, Farlow, M, Rubin, E.H, Heidebrink, J, Hake, A, Ho, G, Schultz, A.N, Schafer, K, Houston, W, Thomas, R, Thal, L.J

“…A phase 1, randomized, double-blind, placebo-controlled, dose escalation study of the purine derivative, AIT-082 (Neotrofin™, NeoTherapeutics) was conducted in…”
Get full text

A 24-week randomized trial of controlled-release physostigmine in patients with Alzheimer's disease by THAL, L. J, FERGUSON, J. M, MINTZER, J, RASKIN, A, TARGUM, S. D

“…To evaluate the safety and efficacy of controlled-release physostigmine, an acetylcholinesterase inhibitor, in patients with probable AD of mild to moderate…”
Get full text

Efficacy and safety of eptastigmine for the treatment of patients with Alzheimer's disease by IMBIMBO, B. P, MARTELLI, P, TROETEL, W. M, LUCCHELLI, F, LUCCA, U, THAL, L. J

“…To evaluate the efficacy and safety of eptastigmine in patients with moderate to moderately severe AD. Eptastigmine is a centrally acting cholinesterase…”
Get full text